BidaskClub cut shares of Genomic Health (NASDAQ:GHDX) from a buy rating to a hold rating in a report issued on Saturday, BidAskClub reports.

Several other research analysts have also commented on GHDX. Piper Jaffray Companies restated a buy rating on shares of Beigene in a research note on Thursday, June 20th. Zacks Investment Research lowered shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a research note on Tuesday, April 23rd. ValuEngine lowered shares of Valero Energy from a hold rating to a sell rating in a research note on Wednesday, May 8th. Canaccord Genuity increased their price target on shares of ServiceNow from $285.00 to $300.00 and gave the stock a buy rating in a research note on Wednesday, May 8th. Finally, Deutsche Bank set a $18.00 price target on shares of Commercial Metals and gave the stock a buy rating in a research note on Thursday, May 30th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $64.86.

Shares of GHDX opened at $56.05 on Friday. The business’s fifty day simple moving average is $55.00. Genomic Health has a 12 month low of $50.77 and a 12 month high of $92.18. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 53.38 and a beta of 1.07. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.05. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The company had revenue of $108.80 million for the quarter, compared to analyst estimates of $106.75 million. During the same quarter in the prior year, the business posted ($0.11) EPS. Genomic Health’s quarterly revenue was up 17.5% on a year-over-year basis. Research analysts anticipate that Genomic Health will post 1.46 EPS for the current year.

In related news, insider Steven Shak sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $51.38, for a total transaction of $2,569,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO G Bradley Cole sold 11,424 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $57.17, for a total transaction of $653,110.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 152,025 shares of company stock valued at $8,175,806. 31.30% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of GHDX. Macquarie Group Ltd. boosted its holdings in Genomic Health by 0.5% in the 4th quarter. Macquarie Group Ltd. now owns 38,200 shares of the medical research company’s stock valued at $2,461,000 after purchasing an additional 200 shares during the period. Royce & Associates LP boosted its holdings in Genomic Health by 22.8% in the 4th quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 273 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Genomic Health by 166.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares during the period. Advisor Group Inc. boosted its holdings in Genomic Health by 34.9% in the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 516 shares during the period. Finally, Quantamental Technologies LLC boosted its holdings in Genomic Health by 19.1% in the 1st quarter. Quantamental Technologies LLC now owns 3,332 shares of the medical research company’s stock valued at $233,000 after purchasing an additional 534 shares during the period. 95.51% of the stock is owned by institutional investors and hedge funds.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: Why do analysts give a neutral rating?

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.